Effect of antihypertensive agents on metabolic syndrome: a systematic review and meta-analysis / Efeitos de antihipertensivos na síndrome metabólica: uma revisão sistemática e metanálise

Authors

  • Luiz Muller Lacerda
  • Yzamara Dutra Guerrieri
  • Diego José Lopes
  • Ana Beatriz Araújo Lucca
  • Marina Fernandes Carvalho
  • Vítor Rodrigues Ribeiro e Silva
  • Leandro Roberto de Macedo
  • Ione Maria de Matos

DOI:

https://doi.org/10.34119/bjhrv4n6-233

Keywords:

Metabolic Syndrome, Antihypertensive Agents, Systematic Review, Meta-Analysis.

Abstract

Background: Metabolic syndrome (MetS) is a chronic disease defined by a set of genetic and environmental factors that determine high cardiovascular risk, being highly prevalent in hypertensive patients. Aim: To identify the efficacy of the association of antihypertensive drugs in hypertensive individuals with MetS. Methods: The systematic review searching the electronic databases Medline/PubMed, Lilacs, BVS and Periódicos Capes with articles published from 2010 to 2020. The registration number of this review at PROSPERO is CRD42021235614. Original articles and clinical randomized trials were included in present review. To calculate the meta-analytic effect measure was used the absolute difference between means using the random effects model with 95% confidence interval. Results: Eight articles were included in this review totaling data from 2,625 patients. In six papers was performed meta-analysis. The selected studies suggest that most combinations of antihypertensive drug classes reduced blood pressure to satisfactory values, and some combinations reduced markers of inflammation, improved lipid and glycemic parameters and reduced the risk of developing diabetes mellitus. The combination therapies between angiotensin receptor blockers (ARB) and calcium channel blockers (CCB), as well as, the combination between CCB and angiotensin converting enzyme inhibitors (ACEI) were well-tolerated and showed satisfactory results in hypertensive patients with metabolic syndrome. Conclusion: based on the results of the present study, we would like to suggest that further studies be carried out to assess the efficacy of the combination between irbesartan and manidipine (ARB and CCB), manidipine and Lisinopril (CCB and ACEI), and between enalapril and lercadipine (ACEI and CCB). These drugs have shown satisfactory results for use in hypertensive patients with MetS.

References

Monte IPd, França SL, Vasconcelos RNOd, Vieira JRdS. Comparação entre quatro diferentes critérios de diagnóstico de síndrome metabólica em indivíduos do Arquipélago do Marajó (Pará, Brasil). Revista da Associação Brasileira de Nutrição - RASBRAN 2019;10(1):96-102.

Azambuja CR, Farinha JB, Rossi DS, Spohr CF, Santos DLd. O diagnóstico da síndrome metabólica analisado sob diferentes critérios de definição. Revista Baiana de Saúde Pública 2015; 39(3):482-496.

Lucca ABA, Carvalho MF, Ribeiro e Silva VR, Magalhães HA, Costa LM, Guerrieri YD, Lopes DJ, Lacerda LM, Assis FSO, De Matos IM, Macedo LR, Bonomo LF, Silva M. Prevalência da síndrome metabólica e seus fatores associados em Governador Valadares (MG, Brasil) – Um estudo piloto. Brazilian Journal of Health Review 2021; 4 (5): 19677-19694.

Ramires EKNM, Menezes RCEd, Longo-Silva G, Santos TGd, Marinho PdM, Silveira JACd. Prevalence and Factors Associated with Metabolic Syndrome among Brazilian Adult Population: National Health Survey - 2013. Arq Bras Cardiol 2018;110(5):455-466.

Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension 2014;64(6):1368-1375.

Brasil. Ministério da Saúde. Vigitel Brasil 2018: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico: estimativas sobre frequência e distribuição sociodemográfica de fatores de risco e proteção para doenças crônicas nas capitais dos 26 estados brasileiros e no Distrito Federal em 2018 [internet]. [acesso em 15 junho 2020]. Disponível em: https://portalarquivos2.saude.gov.br/images/pdf/2019/julho/25/vigitel-brasil-2018.pdf.

I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Arq Bras Cardiol 2005;84(1):3-28.

Segura J, Ruilope LM. A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide. Vasc Health Risk Manag 2013;9:521-528.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:65–94. doi: 10.7326/0003- 4819- 151- 4- 200908180- 00136.

Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Chapter 3: Systematic reviews of effectiveness. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020. Available from https://synthesismanual.jbi.global.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.

Franklin SS, Neutel JM. Efficacy and Safety of Irbesartan ⁄HCTZ in Severe Hypertension According to Cardiometabolic Factors. J Clin Hypertens 2010; 12:487–494.

Fogari R, Zoppi A, Ferrari I, Mugellini A, Preti P, Derosa G. Time to Achieve Blood Pressure Goal with a Combination Versusa Conventional Monotherapy Approach in Hypertensive Patients with Metabolic Syndrome. Clinical and Experimental Hypertension 2010; 32(5): 245–250

Martinez-Martin FJ, Rodriguez-Rosas H, Peiro-Martinez I, Soriano-Perera P, Pedrianes-Martin P, Comi-Diaz C. Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. J Hum Hypertens 2010; 25:346–353.

Martinez-Martin FJ, Macias-Batista A, Comi-Diaz C, Rodriguez-Rosas H, Soriano-Perera P, Pedrianes-Martin P. Effects of Manidipine and its Combination with an ACE Inhibitor on Insulin Sensitivity and Metabolic, Inflammatory and Prothrombotic Markers inHypertensive Patients with Metabolic Syndrome - The MARCADOR Study. Clin Drug Investig 2011; 31 (3): 201-212

Spinar J, Vitovec J, Soucek M. Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study) Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014; 158(3):412-421.

Ghiadoni L, Bruno RM, Cartoni G, Stea F, Magagna A, Virdis A, et al. Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome. Vascul Pharmacol 2017; 92:16-21.

Brown MJ, Williams B, Morant SV, Webb DJ, Caulfield MJ, Cruickshank JK, et al; British Hypertension Society's Prevention and Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016; 4(2):136-47.

Napoli C, Omboni S, Borghi C. Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with establishedmetabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in AdvancedMEtabolic Syndrome). Journal of Hypertension 2016; 34(11):2287-97

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97.

Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23):2417-28.

Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29(12):2592-7.

Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet 2007; 369(9572):1518.

Bakris G, Stockert J, Molitch M, Zhou Q, Champion A, Bacher P, et al. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab 2009; 11(3):177-187.

Racine N, Hamet P, Sampalis JS, Longo N, Bastien N. A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome. J Hum Hypertens 2010; 24(11):739-48.

Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised Trial against atenolol. Lancet 2002; 359(9311):995-1003.

Petrella R, Michailidis P. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management. Clin Ther 2011;33(9):1190-203.

Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007; 6:12.

Blood Pressure Lowering Treatment Trialists’ Collaboration Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25(7):1524.

Richy FF, Laurent S. Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials. Blood Press. 2011 Feb;20(1):54-9.

G. Schillaci, M. Pirro, G. Vaudo, et al., Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension, Hypertension 45 (2005) 1078–1082.

Y. Plantinga, L. Ghiadoni, A. Magagna, et al., Peripheral wave reflection and endothelial function in untreated essential hypertensive patients with and without the metabolic syndrome, J. Hypertens. 26 (2008) 1216–1222.

Tolezani EC, Costa-Hong V, Correia G, Mansur AJ, Drager LF, Bortolotto LA. Determinants of functional and structural properties of large arteries in healthy individuals. Arq Bras Cardiol. 2014;103(5):426-32.

Sociedade Brasileira de Cardiologia; Sociedade Brasileira de Hipertensão, Sociedade Brasileira de Nefrologia. VII Diretrizes Brasileiras de hipertensão. Arq Bras Cardiol. 2016;107(1 supl.3):1-82.

Thomas JP, Thomson WH. Comparison of thiazides and amiloride in treatment of moderate hypertension. BMJ (Clin Res Ed) 1983;286: 2015–18.

Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 5;356(9228):514.

Published

2021-11-29

How to Cite

LACERDA, L. M.; GUERRIERI, Y. D.; LOPES, D. J.; LUCCA, A. B. A.; CARVALHO, M. F.; E SILVA, V. R. R.; DE MACEDO, L. R.; DE MATOS, I. M. Effect of antihypertensive agents on metabolic syndrome: a systematic review and meta-analysis / Efeitos de antihipertensivos na síndrome metabólica: uma revisão sistemática e metanálise. Brazilian Journal of Health Review, [S. l.], v. 4, n. 6, p. 26549–26570, 2021. DOI: 10.34119/bjhrv4n6-233. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/40326. Acesso em: 28 mar. 2024.

Issue

Section

Original Papers